Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 10 January 2013 | By Louise Zornoza,
Canada's Therapeutic Products Directorate (TPD) has announced that as of 1 February 2013 it will be replacing the Integrated Review Process (IRP) that has been used for screening generic Abbreviated New Drug Submissions (ANDS) and supplements (SANDS) with updated screening criteria.
The aim is to better focus review resources on the review of complete submissions so as to reduce and ultimately eliminate the current backlog of generic drug submissions, Canadian regulatory officials said.
A key component to the new screening process will include an attestation checklist for use by generic sponsors that is intended to ensure that the key required information is being provided in the generic application. In the updated screening process, sponsors will also be required to confirm through the attestation form that Drug Master Files and the required Letters of Authorization have been provided. If the DMF is not in order (fees paid, accessible), a Screening Deficiency Notice (SDN) will be issued. The "Closed" portion of the DMFs will no longer be verified at screening.
The screening process will continue to be carried out in accordance with the Guidance for Industry: Management of Drug Submissions (MDSG). The sponsor will be notified of significant deficiencies revealed during screening via either a request for clarification or an SDN. Once all of the requested information has been received, the submission will be accepted for review.
Implementation of the updated screening criteria and the attestation form will start with all new ANDS and supplements received by the Office of Submissions and Intellectual Property as of 1 February 2013. The attestation form, however, will be accepted for submissions filed from 2 January 2013 onwards.
Tags: ANDA
Regulatory Focus newsletters
All the biggest regulatory news and happenings.